Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid

Regeneron Pharmaceuticals, Inc.
Sanofi SA Sponsored ADR

Regeneron Pharmaceuticals, Inc.

REGN

0.00

Sanofi SA Sponsored ADR

SNY

0.00
  • Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo
  • BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions
  • BP is the seventh approved indication for Dupixent in Japan
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.